epidermolysis bullosa


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to epidermolysis bullosa: Epidermolysis bullosa simplex

epidermolysis bullosa

[‚ep·ə·dər′mäl·ə·səs bu̇′lō·sə]
(medicine)
A congenital skin disease characterized by the development of vesicles and bullae upon slight, or even without, trauma.
References in periodicals archive ?
A representative from the charity Dystrophic Epidermolysis Bullosa Research Association (DEBRA) was also at the ceremony, along with Glyn Davies, minister of the American Embassy.
was the first biotech to receive "Breakthrough Therapy" designation for SD-101 from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with Epidermolysis Bullosa.
The Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA), is the only national non-profit dedicated to funding research and providing services and programs for those with Epidermolysis Bullosa (EB) - The Worst Disease You've Never Heard Of.
Robert Ryan, to the board of directors of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA).
Epidermolysis Bullosa is the term used to describe a number of genetic disorders whose principal characteristic is fragile skin.
The event marks the beginning of National Epidermolysis Bullosa Awareness Week, which was legislated by Congress in 1984 and occurs annually from October 25 through October 31.
DEBRA UK works on behalf of those with the blistering condition epidermolysis bullosa, and is celebrating its 25th anniversary this year.
There is a tremendous need for novel treatment options for treating the debilitating skin effects in patients with Epidermolysis Bullosa.
DEBRA UK works on behalf of those with the skin blistering condition, Epidermolysis Bullosa (EB), and is marking its 25th anniversary this year.
ABOUT EPIDERMOLYSIS BULLOSA ( EB) Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder.
Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.
The finding came about because roughly two-thirds of children with a blistering skin disorder called recessive dystrophic epidermolysis bullosa, or RDEB -- caused by a mutation that leads to an altered or missing collagen VII protein -- develop a type of skin cancer called squamous cell carcinoma.
Full browser ?